Journal
CRITICAL CARE MEDICINE
Volume 49, Issue 8, Pages 1293-1302Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCM.0000000000004948
Keywords
cardiogenic shock; heart failure; myocardial infarction; shock; staging; stratification
Categories
Funding
- Abbott Corporation
- National Institutes of Health (NIH)
- NIH
- Alnylam Pharmaceuticals
- Akcea Therapeutics
- Pfizer Inc
- Eidos Therapeutics
- Abiomed Critical Care Advisory Board
- Abbott
- Abiomed
- Medtronic
- CareDx Paragonix
- TelaDoc-Best Doctors
- OakstoneEBIX
- McGraw-Hill Publishing
Ask authors/readers for more resources
This study investigated whether the implementation of the 2019 Society for Cardiovascular Angiography and Interventions clinical cardiogenic shock staging criteria can discriminate mortality in a contemporary population with or at-risk for cardiogenic shock. The results showed that this staging system effectively stratifies mortality risk and could be leveraged for future clinical research, providing valuable information for risk assessment and treatment selection in patients with cardiogenic shock.
OBJECTIVES: Cardiogenic shock presents with variable severity. Categorizing cardiogenic shock into clinical stages may improve risk stratification and patient selection for therapies. We sought to determine whether a structured implementation of the 2019 Society for Cardiovascular Angiography and Interventions clinical cardiogenic shock staging criteria that is ascertainable in clinical registries discriminates mortality in a contemporary population with or at-risk for cardiogenic shock. DESIGN: We developed a pragmatic application of the Society for Cardiovascular Angiography and Interventions cardiogenic shock staging criteria-A (at-risk), B (beginning), C (classic cardiogenic shock), D (deteriorating), or E (extremis)-and examined outcomes by stage. SETTING: The Critical Care Cardiology Trials Network is an investigator-initiated multicenter research collaboration coordinated by the TIMI Study Group (Boston, MA). Consecutive admissions with or at-risk for cardiogenic shock during two annual 2-month collection periods (2017-2019) were analyzed. PATIENTS: Patients with or at-risk for cardiogenic shock. MEASUREMENTS AND MAIN RESULTS: Of 8,240 CICU admissions reviewed, 1,991 (24%) had or were at-risk for cardiogenic shock. Distributions across the five stages were as follows: A: 33%; B: 7%; C: 16%; D: 23%; and E: 21%. Overall in-hospital mortality among patients with established cardiogenic shock was 39%; however, mortality varied from only 15.8% to 32.1% to 62.5% across stages C, D, and E (Cochran-Armitage p(trend) < 0.0001). The Society for Cardiovascular Angiography and Interventions stages improved mortality prediction beyond the Sequential Organ Failure Assessment and Intra-Aortic Balloon Pumpin Cardiogenic Shock II scores. CONCLUSIONS: Although overall mortality in cardiogenic shock remains high, it varies considerably based on clinical stage, identifying stage C as relatively lower risk. We demonstrate a pragmatic adaptation of the Society for Cardiovascular Angiography and Interventions cardiogenic shock stages that effectively stratifies mortality risk and could be leveraged for future clinical research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available